Reviewing Pulmonx (LUNG) & The Competition

Pulmonx (NASDAQ:LUNG) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Pulmonx to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Pulmonx and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1	0	3	0	2.50
Pulmonx Competitors	4281	10558	18338	829	2.46

Pulmonx presently has a consensus price target of $7.67, suggesting a potential upside of 173.81%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.83%. Given Pulmonx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Pulmonx is more favorable than its rivals.

Valuation & Earnings

This table compares Pulmonx and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pulmonx	$90.50 million	-$54.00 million	-2.77
Pulmonx Competitors	$1.87 billion	$138.21 million	12.61

Pulmonx’s rivals have higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Pulmonx and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-47.93%	-98.23%	-35.89%
Pulmonx Competitors	-276.78%	-149.08%	-21.73%

Institutional & Insider Ownership

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Pulmonx has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Pulmonx’s rivals have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Summary

Pulmonx rivals beat Pulmonx on 7 of the 13 factors compared.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.